Related Experiment Video
Updated: Jun 24, 2026

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
Published on: September 25, 2019
Treatment of chronic hepatitis B: focus on telbivudine
Yanni Y N Lui1, Henry L Y Chan
1Department of Medicine and Therapeutics and Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong SAR, China.
Abstract:
Chronic hepatitis B is a worldwide health problem. Research interests have focused on the development of potent and safe antiviral agents with low resistance rates. Among these, telbivudine is an oral nucleoside analogue with specific activity against hepatitis B virus DNA polymerase. Various prospective, randomized clinical trials have demonstrated the potent efficacy of telbivudine in suppressing viral replication and achieving hepatitis B e antigen seroconversion. Telbivudine was also proved to be superior to lamivudine and adefovir dipivoxil. This article provides an overview of the pharmacokinetics, clinical efficacies, resistance profile and safety of telbivudine. A comparison of telbivudine with other oral antiviral agents is also highlighted.
Related Concept Videos
Hepatitis
Viral Hepatitis I: Introduction
Antiviral Nucleoside Inhibitors
Retrovirus Life Cycles
Inhibitors of Viral Protein Synthesis
Pulmonary Tuberculosis V
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the progression...
